, and non-HDL-C were evaluated to determine their ability to predict cardiovascular disease (CVD) risk with pravastatin treatment. Methods: We conducted a large-scale randomized primary prevention trial in Japan (MEGA Study), in which we randomly allocated 7832 mild hypercholesterolemic patients to diet alone (n 3966) and diet plus pravastatin groups (n 3866) and followed them for an average of 5 years. We compared baseline levels and the CVD incidence in the diet alone group, and time-dependent receiver operating characteristic curves in the overall population. To determine the best parameter for predicting the efficacy of pravastatin, the diet plus pravastatin group was divided into tertiles to compare lipid parameters and CVD incidence versus the diet alone group. Results: Significantly graded correlations were found between CVD and LDL-C/HDL-C and non-HDL-C. Significantly more CVD events were associated with LDL-C/HDL-C 186 mg/dL and LDL-C/HDL-C 2.9. Furthermore, LDL-C/HDL-C or non-HDL-C was more predictive than LDL-C. By measuring LDL-C/HDL-C or non-HDL-C, we allocated 32% of the diet plus pravastatin group into a different risk category. The lowest significant incidence of CVD was found in patients with LDL-C 119.8-133.4 mg/dL, LDL-C/HDL-C 1.9, and non-HDL-C 145.2-160.8 mg/dL. Conclusion: Non-HDL-C and LDL-C/HDL-C have a greater ability to predict CVD risk in mild-tomoderate hypercholesterolemic Japanese individuals than LDL-C, and are more useful to evaluate the effect of pravastatin; however, these parameters should be interpreted independently when assessing CVD risk.
Introduction
The strong relation between the low-density cholesterol (LDL-C) level and the incidence of cardiovascular disease (CVD) is well established 1, 2) . LDL-C is therefore the main parameter used in treatment guide-lines [3] [4] [5] and for some risk assessment tools of CVD 6, 7) . To determine LDL-C in patients, Friedewald's formula 8) is generally used worldwide, although its accuracy is limited by the influence of triacylglyceride (TG) levels, which can be affected by food intake. Thus, the use of non-high-density lipoprotein cholesterol (non-HDL-C) as an alternative parameter was suggested by the US Adult Treatment Panel (ATP ) guidelines 3) . According to ATP , the non-HDL-C target is 30 mg/dL above the LDL-C target. Another alternative parameter is the ratio of LDL-C to HDL-C (LDL-C/HDL-C), which has been reported to be strongly associated with CVD and is thought to be a better predictor of future CVD than LDL-C 9, 10) . Although the 2007 European Society of Cardiology (ESC) guideline on CVD prevention in clinical practice presented the benefit of non-HDL-C and LDL-C/HDL-C as predictive parameters, no target level was given because of the lack of clinical trial evidence 4) . Moreover, current Japanese guidelines for the prevention of atherosclerotic disease do not suggest using non-HDL-C and LDL-C/HDL-C because of a lack of data 5) . Thus, there are few data to define which lipid parameter is best to predict CVD and to define target levels. In this subanalysis we aimed to compare the predictive power of non-HDL-C and LDL-C/ HDL-C for CVD, and to evaluate the relationship between these parameters and the effect of pravastatin treatment using historical data from the MEGA Study, a large-scale primary prevention clinical trial of pravastatin conducted in Japan.
Methods
The design, baseline characteristics, and major outcomes of the prospective, randomized, open-label, blinded endpoints ("PROBE") MEGA Study have been described elsewhere 11, 12) . Briefly, in the MEGA Study, 7832 patients (2476 men and 5356 postmenopausal women) aged 40-70 years with mild-to-moderate hypercholesterolemia (total cholesterol [TC] level, 220-270 mg/dL) and no prior history of CVD were randomly allocated to receive diet therapy alone or diet plus pravastatin (10-20 mg/day; the approved dosage in Japan) for a mean follow-up period of 5.3 years. Patients in both arms were counseled to follow the National Cholesterol Education Program (NCEP)
Step diet 13) throughout the study period. Treatment in the diet plus pravastatin group was initiated at pravastatin 10 mg/day. During follow-up, the dose of pravastatin could be adjusted by the treating physician, with titration up to 20 mg/day if TC did not decrease to ≤ 220 mg/dL, in compliance with Japanese dosing instructions. Patients whose TC remained 270 mg/dL, even after increase of the assigned treatment, could be switched to other aggressive treatments, including other statins. Concomitant treatment for complications was not restricted in either group. The primary composite endpoint was the first occurrence of coronary heart disease (CHD) events, including fatal and nonfatal myocardial infarction, angina pectoris, cardiac/sudden death, and coronary revascularization. Secondary endpoints included all strokes, CHD plus ischemic stroke, all CVD events, and total mortality. Patients were evaluated by their attending physicians at 1, 3, and 6 months after the start of follow-up and every 6 months thereafter. Health checkups at each clinic visit included biochemical tests and assessment of patients' compliance with dosing. For each event, detailed information was obtained from physicians and evaluated by the Endpoints Committee under blinding according to established criteria 11) . Throughout the study period, TC, HDL-C, TG, and lipoprotein(a) (Lp[a]) levels were centrally measured at the same laboratory using methods standardized by the Centers for Disease Control and Prevention (Atlanta, GA). LDL-C was assessed by Friedewald's formula 8) .
In this subanalysis, the 3966 patients in the diet group were divided into quartiles according to baseline TC, LDL-C, HDL-C, TG, non-HDL-C levels, TC/HDL-C, and LDL-C/HDL-C ratios. The incidences of CHD, stroke, and cardiovascular events in each quartile were compared. Furthermore, to compare the predictive ability of these parameters, the weighted averaged area under the curve ("C-statistics") obtained from the time-dependent receiver operating characteristic curve (ROC) was estimated using data from all 7832 patients included in the trial 14) . In addition, the relation between on-treatment LDL-C, LDL-C/HDL-C, and non-HDL-C in the diet plus pravastatin group and the incidence of CVD events were compared. The 3866 patients in the diet plus pravastatin group were divided into tertiles according to their on-treatment LDL-C, LDL-C/HDL-C, and non-HDL-C levels and compared with the diet group. All survival analyses were based on the Cox proportional hazards model at 5 years adjusted by baseline risk factors such as sex, age, baseline level of the target on-treatment lipid parameter, baseline HDL-C level, diabetes, hypertension, and smoking. The hazard ratios (HRs) and 95% confidence intervals (95%CIs) were assessed. Events occurring during the first 6 months after follow-up began were excluded from this analysis because they might not be associated with treatment. On-treatment lipid levels were defined as the cumulative average during the period from the first month to the established evaluation point. In all analyses, when the LDL-C level was not measured as scheduled, it was evaluated using the multiple regression model; covariates were the treatment arm, sex, age, baseline lipid values (TC, LDL-C, HDL-C, TG), diabetes, hypertension, treatment history of hyperlipidemia, body mass index, cigarette smoking, alcohol drinking, and the most recently recorded LDL-C.
Results
Relations between baseline lipid parameters and CHD, stroke, and CVD events are shown in Table 1 . The group with the highest baseline LDL-C level was significantly ( p 0.05) associated with the prevalence of CVD; however, no association was found for CHD and stroke. Patients with baseline HDL-C levels in the second or higher groups displayed a significant association with CHD and CVD. Moreover, the ratios of TC/HDL-C and LDL-C/HDL-C, as well as non-HDL-C levels, were all found to be significantly related to CVD and CHD in the third or higher groups. Baseline non-HDL-C was the only parameter related to a significant increase in stroke (highest quartile, 197.7-234.4 mg/dL), with an HR of 2.06 ( p 0.05).
All time-dependent ROC curves were within a narrow range: between 0.74 and 0.77 for CHD, 0.72 and 0.74 for stroke, and 0.73 and 0.77 for CVD (Fig. 1) . Estimated C-statistics for each parameter in the ROC curves are shown in Table 2 . For CHD, stroke, and CVD, the lowest C-statistics were for TC and the highest for HDL-C. C-statistics for TC/ HDL-C, LDL-C/HDL-C ratios and non-HDL-C levels were similar and higher than those for LDL-C and TG alone in relation to CVD, CHD, and stroke.
In the diet alone group, the relation between CVD events and the LDL-C/HDL-C ratio and non-HDL-C was further examined by dividing the patients according to tertiles of each lipid parameter ( Table 3) . This distribution showed that 68% of patients were allocated to the same category (low, moderate, or high) using either lipid parameter (LDL-C/HDL-C or non-HDL-C); therefore, 32% of the patients were allocated to different risk categories when using either LDL-C/HDL-C or non-HDL-C. The moderate and high LDL-C/HDL-C tertiles (≥ 2.37) and high tertile of non-HDL-C (≥ 171.6 mg/dL) seemed to be associated with a higher incidence of CVD. Furthermore, low LDL-C/HDL-C plus high non-HDL-C and moderate LDL-C/HDL-C plus low non-HDL-C seemed to be associated with higher CVD incidence.
To determine which parameter best evaluates the effect of pravastatin therapy relationships on the achieved level of LDL-C, LDL-C/HDL-C, and non-HDL-C, the incidence of CVD events was evaluated by comparing diet plus pravastatin versus diet groups (Fig. 2) . The average baseline LDL-C, non-HDL-C, and LDL-C/HDL-C levels in the diet group were 156.5 mg/dL, 185.1 mg/dL and 2.9, respectively, decreasing to 151.1 mg/dL, 178.9 mg/dL, and 2.8, whereas the average baseline LDL-C, non-HDL-C, and LDL-C/HDL-C levels in the diet plus pravastatin group were 156.7 mg/dL, 185.1 mg/dL and 2.9, respectively, decreasing to 128.0 mg/dL, 154.3 mg/dL, and 2.3. Similar risk reduction profiles were found for each lipid parameter for stroke, CHD, and CVD. The largest risk reduction for CVD was found for the moderate LDL-C tertile (119.9-133.4 mg/dL; HR, 0.57; p 0.01), lowest LDL-C/HDL-C tertile ( 2.0; HR, 0.57; p 0.04), and moderate tertile of non-HDL-C (145.2-160.8 mg/dL; HR, 0.48; p 0.002). A 23% risk reduction for CVD was found in the lowest achieved LDL-C tertile (≤ 119.7 mg/dL) and 35% risk reduction in the lowest non-HDL-C tertile (≤ 145.0 mg/dL).
Discussion
The purpose of this study was to determine the best lipid parameter to predict CVD among LDL-C, LDL/HDL, and non-HDL-C and to evaluate the benefit of pravastatin therapy in patients with mild-tomoderate hypercholesterolemia. The predictability of future CVD events has been well assessed in previous epidemiological studies of the general population 15, 16) . These studies demonstrated the high reliability of HDL-C in predicting future CVD, and ratios incorporating HDL-C showed greater predictability of CVD than LDL-C or TG alone. Consistent with this, in this study, in patients with mild to moderate hypercholesterolemia, their HDL-C provided the greatest predictability in determining CVD events, and consequently high predictability was found in the ratios of TC/HDL-C and LDL-C/HDL-C, as well as non-HDL-C. Comparatively, these results suggest that LDL-C or TG levels alone are lacking in predictability when comparing the C-statistics, indicating that parameters related to HDL-C are more effective in providing accurate risk assessment of CVD even in mild to moderate hyperlipidemia. In this analysis a significant relation was found in non-HDL-C 186 mg/dL and LDL-C/HDL-C 2.9; therefore, they can be considered as the cut off in the prediction of future CVD.
Recently, the non-HDL-C and LDL-C/HDL-C The HRs were estimated against the lowest quartile using the Cox proportional hazards models adjusted by treatment group, age, sex, BMI, diabetes, hypertension, and smoking. CHD, coronary heart disease; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; NHDL, non high-density lipoprotein cholesterol; BMI, body mass index.
ratio were recognized as useful parameters to predict future CVD risk and to evaluate the effects of statins. Despite this promising beginning, little evidence currently exists that extrapolates and confirms the predictive capacity of these parameters. The current analysis found no marked difference in the predictive ability of LDL-C/HDL-C and non-HDL-C; however, additional analysis to evaluate consistency across the patient population in each tertile of non-HDL-C or LDL-C/ HDL-C ratio revealed that the risk prediction would be incorrect in 32% of the diet alone group if only one of the parameters was used. Therefore, although LDL/HDL-C and non-HDL-C are superior predictors of CVD compared with LDL-C, in support of previous work reported by other groups [17] [18] [19] [20] , our data also indicate that individual CVD risk could be incorrectly predicted by only using non-HDL-C or the LDL-C/HDL-C ratio alone.
There are few data regarding the relationship between on-treatment levels with statins of each lipid parameter and CVD risk in Japanese patients. Our analysis showed little difference between achieved, ontreatment LDL-C, LDL-C/HDL-C ratio, and non-HDL-C and CVD risk reduction, and also CHD or stoke risk reduction. Significant or nearly significant risk reduction of CVD was found for LDL-C 133.4 mg/dL, non-HDL-C 160.8 mg/dL, and LDL-C/ HDL-C ratio 2.0. The benefit of statin therapy against CVD has been well established by numerous large-scale studies [21] [22] [23] [24] [25] [26] [27] [28] [29] and meta-analyses 30, 31) that have also suggested LDL-C target levels used by current guidelines and showed that non-HDL-C and LDL-C/HDL-C are associated with CVD risk. The ATP guidelines 3) state that non-HDL-C is a secondary target, and the level is set by adding 30 mg/dL to LDL-C target levels ( 130 mg/dL for moderate/ moderately high risk, 160 mg/dL for low risk). Although current guidelines do not state the target LDL-C/HDL-C ratio, a previous report 32) demonstrated that a ratio 2.0 is associated with preventing plaque progression. We showed that non-HDL-C 160 mg/ dL and an LDL-C/HDL-C ratio 2.0 may be appropriate targets in primary prevention.
There are a number of limitations to this subanalysis. First, the narrow baseline distribution of TC levels due to the inclusion criteria limits the application of our results to patients within this range of TC levels. On the other hand, however, about 70% of the 20 million ambulatory patients with hypercholesterolemia in Japan fall within this range. Second, a previous report demonstrated that TG is associated with CVD, and incorporating TG into the assessment model improves the ability to predict future CVD. 33) . This may be due to the narrow range of the TC. Third, we found more stroke and CVD events in the lowest tertile of LDL-C, non-HDL-C, and LDL-C/HDL-C parameters compared with the second tertile groups. Furthermore, the number of incidences between the lowest tertile and second tertile was not statistically significant, and an LDL-C level 100 mg/dL was achieved by only 5% of patients during the 5-year follow-up in the MEGA study. Thus, the relationship between CVD and more aggressive reductions in LDL-C, LDL-C/HDL-C, and non-HDL-C remains undefined, as this was not studied in this low-risk population. Lastly, hsCRP (a commonly used CVD risk parameter) was not included as it was not included when the MEGA study was designed.
In conclusion, non-HDL-C and LDL-C/HDL-C are better predictors of CVD risk than LDL-C in Japanese patients with mild-to-moderate hypercholesterolemia; however, the parameters should be used jointly rather than alone for better prognostic value. Non-HDL-C and the LDL-C/HDL-C ratio are useful to evaluate the beneficial effects of pravastatin therapy. 
